Preclinical Bioanalytical Aspects of AAV Gene Therapies

Time: 11:45 am
day: Day One

Details:

  • Understanding the role of DMPK to model the distribution of AAV gene therapies
  • Evaluate in vitro assays for bioanalysis and to the best select vector and way
    forward
  • Discuss immunogenicity considerations

Speakers: